x

¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

Indexada en:

Index Medicus Medline, IME, Embase, Bibliomed, EMBASE/Excerpta Medica, Alert, International Pharmaceutical Abstracts, ADIS LMS Drug Alert, Inside Conferences, SCOPUS

Métricas

  • SCImago Journal Rank (SJR):0,21
  • Source Normalized Impact per Paper (SNIP):0,379
Farm Hosp 2007;31:206-11 - DOI: 10.1016/S1130-6343(07)75375-8
Interrupción del tratamiento con la terapia combinada lopinavir/ritonavir en pacientes VIH+
Interruption to treatment with combined lopinavir-ritonavir therapy in HIV positive patients
G. Sanfélix Gimenoa, A. Rocher Millab, G. Roldán Garcíaa, J. Sanfélix Genovésc, I. Pereiro Berenguerd, S. Peiró Morenoa
a Escuela Valenciana de Estudios de la Salud. Valencia
b Servicio de Farmacia. Hospital Arnau de Vilanova. Valencia
c Centro de Salud de Nazaret. Unidad de Investigación de la Unidad Docente de Medicina Familiar y Comunitaria. Valencia
d Centro de Salud de Trafalgar. Unidad de Investigación de la Unidad Docente de Medicina Familiar y Comunitaria. Valencia
Resumen
Objective: To describe the extent of interruptions to treatment with therapies which include the combination of lopinavirritonavir within the SNS (Spanish National Health System), as well as identify the causes of these interruptions and analyse the factors associated with the same. Method: Retrospective cohort of 197 seropositive patients, who began treatment with lopinavir-ritonavir between January 2000 and October 2002. The patients attended the outpatient pharmaceutical care unit and were followed-up until December 2002. Interruptions and their causes were identified and the factors associated with the interruption were analysed using proportional hazard models. Results: The mean follow-up period was 263 days and 38.6% of patients interrupted therapy. The most common causes of interruption were intolerance (30.3%), non-compliance (21.1%) and therapy failure (5.26%). The mean treatment period was 487 days (95% CI: 432 to 542) and 50% of patients who interrupted treatment did so within the first 4 months. No associations were found between patient or treatment characteristics and the risk of interruption. Conclusions: The percentage of interruptions was lower than those in other observational studies, but greater than those in clinical trials. The significance of the causes of interruption was similar and no factor associated with the risk of interruption was found.
Palabras clave
VIH, Terapia antirretroviral, Inhibidores de la proteasa, Interrupción, Causas de interrupción
Keywords
HIV, Antiretroviral therapy, Protease inhibitors, Interruption, Causes of interruption
El Texto completo solo está disponible en PDF